Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025Frontiers in PharmacologyOpen Access

The efficacy and safety of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis based on randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCong ShaoQWQuan WanJGJia Guo

Discussion

Loading...

Member takes

Overview

Systematic review shows cabazitaxel improves overall survival and progression-free survival in mCRPC, indicating the need for careful monitoring of adverse events.

Key Points

  • Cabazitaxel significantly improves overall survival in mCRPC compared to androgen receptor pathway inhibitors, with a hazard ratio of 1.50.
  • Analysis of 13 randomized controlled trials showed cabazitaxel improves progression-free survival compared to multiple treatments like CAB + CP and ARPI.
  • The quality assessment of included studies indicated a low overall risk of bias, confirming the reliability of the findings.
  • Combining cabazitaxel with other therapies may enhance efficacy but increases the risk of serious adverse events, warranting caution.

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/689a0c7be6551bb0af8d04b2https://doi.org/10.3389/fphar.2025.1586650
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis2025
  2. 2Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis2025
  3. 3Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis2025
  4. 4Editorial Comment on “Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis”2025
  5. 5Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel2025